Wednesday, July 8, 2026

pharma · Major Depressive Disorder · Migraine · AXSM

Axsome Therapeutics

Axsome Therapeutics is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker AXSM. Primary therapeutic focus areas include Major Depressive Disorder, Migraine, Agitation in Patients With De

One World Trade Center, New York, NY 10007, US HQ
2012 Founded
981 Employees
Public company Type
AXSM · NYSE Ticker
Company details
Status
Public
HQ
One World Trade Center, New York, NY 10007, US
Founded
2012
Employees
981
Programs
28
Drugs
12
Patents
162
Clinical program

Solriamfetol

Approved · small molecule · Excessive Daytime Sleepiness

Solriamfetol for Excessive Daytime Sleepiness is a Approved program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).

← All Axsome Therapeutics projects Approved small molecule completed

Internal code JZP110-405

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Axsome Therapeutics
Phase
Approved
Modality
small_molecule
Indication
Excessive Daytime Sleepiness
Status
completed
Trials
1